measured by the participant-reported Nasal Congestion Score evaluated as part of the daily Nasal Polyposis Symptom Diary. The ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

This can lead to symptoms like nasal congestion or discharge, post-nasal drip, headache, and pressure around your eyes, forehead, and cheeks. Chronic ... not respond to treatment, your doctor ...

Common symptoms include nasal congestion ... Dr Pirzada explained. This chronic allergic reaction leads to continuous ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Experts generally agree that nasal polyps and any related health conditions can decrease a person’s quality of life by causing symptoms such as nasal congestion and facial pressure. Up to 13 ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...